<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Robert C. Doebele | Ruth Palmer Lab</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/robert-c.-doebele/</link><atom:link href="https://deploy-preview-3--ruthpalmerlab.netlify.app/author/robert-c.-doebele/index.xml" rel="self" type="application/rss+xml"/><description>Robert C. Doebele</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Thu, 01 Sep 2022 00:00:00 +0000</lastBuildDate><image><url>https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.png</url><title>Robert C. Doebele</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/robert-c.-doebele/</link></image><item><title>Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/</link><pubDate>Thu, 01 Sep 2022 00:00:00 +0000</pubDate><guid>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/</guid><description/></item></channel></rss>